2020 IPO
Schrodinger Stock
Computational drug design
Sign up today and learn more about Schrodinger Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Schrodinger Stock
Schrödinger is a scientific developer of computational drug design for pharmaceutical and biotechnology research.
Investors
Baron Capital Management
Qiming Venture Partners
Deerfield
WuXi AppTec
Bill & Melinda Gates Foundation
Apeel Sciences, Pivot Bio, Butterfly Network, Schrodinger, Evolve Biosystems, Heliogen
Funding History
| April 2010 | $10.0M |
|---|---|
| December 2012 | $20.0M |
| June 2015 | $22.0M |
| January 2019 | $85.0M |
Management
Chief Biomedical Scientist
Karen Akinsanya
Chief Financial Officer
Joel Lebowitz
Chief Business Officer
Cony D'Cruz
Press
Fast Company - Sep, 25 2015
The Tangled History And Mysterious Legality Of "Happy Birthday"techweekeurope - Sep, 4 2015
Intel Invests ÂŁ33m In Quantum Computing Researchgizmodo - Jul, 13 2015
The Material That Both Conducts Electricity – and Doesn’tgizmodo - May, 25 2015
You'll Feel Way Smarter After Watching These YouTube Physics LessonsEquityZen Recognized As:
